Tempus Ai, Inc. · NASDAQ:TEM
Tempus Ai — Technical Presentation (October 2023)
7 slides from Tempus Ai's technical presentation, October 2023
Slide 1: Multi-state Modeling of Tricuspid Regurgitation Disease Progression Rate using an EHR-integrated NLP Platform
Multi-state Modeling of Tricuspid Regurgitation Disease Progression Rate using an EHR-integrated Natural Language Processing Platform OMAR KHALIQUE, MD, FACC, FASE, FSCCT, FSCMR, FSCAI DIRECTOR, DIVISION OF CARDIOVASCULAR IMAGING DIRECTOR, ADVANCED CARDIOVASCULAR IMAGING FELLOWSHIP SAINT FRANCIS HOS
Slide 2: Background
Background ► Tricuspid Regurgitation is a morbid disease with negative outcomes ► Disease progression is poorly characterized ► Understanding disease progression is crucial for optimizing patient outcomes and determining timing of intervention
Slide 3: Methods
Methods ► Tempus Next (Tempus Labs Inc, Chicago, IL) studied patients with TR at baseline between August 2018 to December 2021 with a follow up echo until May 2023 ► Demographic and Echo indices were parsed from the Echo report using natural language processing ► The endpoint was progression to seve
Slide 4: Results
Results ► 52,090 patients (93,335 echoes) were retrospectively analyzed and screened for TR, (8,041 mild; 1,005 mild-moderate; 1,230 moderate; 280 moderate-severe), with an average observation window of 557 days (range: 31-1723 days) ► 27% of patients that were moderate-severe at the time of their i
Slide 5: Results
Results No Tricuspid Regurgitation Mild Tricuspid ad Regurgitation 2.65 years (95% CI 2.55-2.75) in this state Mild-Mod Tricuspid Regurgitation 0.92 years (95% CI 0.89-0.96) in this state Moderate Tricuspid Regurgitation Mod-Sev Tricuspid a Regurgitation 2.34 years a: (95% CI 2.20-2.49) in this stat
Slide 6: Results
Results ► Patients indexed at moderate-severe TR had 10%, 16% and 24% probability of progression within 6 months, 1 year, and 2 years, respectively. ► However, the time to progression was not significantly different when comparing patients indexed at mild, mild-moderate, moderate, or moderate-severe
Slide 7: Conclusions
Conclusions ► The study findings provide insights on the progression of TR which can be incorporated into future efforts to assess frequency of follow up imaging ► These findings highlight the importance of vigilant monitoring which can help guide future tricuspid intervention trials. ► Further rese